Compare Cardinal Health Inc (CAH) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs 22nd Century Group Inc — how do they compare? Cardinal Health Inc trades at $234.2 (market cap $55.88B), while 22nd Century Group Inc trades at $4.33 (market cap $1.52M). The key difference: Cardinal Health Inc is far larger — about 36763.2× 22nd Century Group Inc's market cap, and Cardinal Health Inc pays a 0.86% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| CAH | XXII | |
|---|---|---|
Market Cap | $55.88B | $1.52M |
Sector | Health | Technology |
52-Week High | $240.26 | $801.00 |
52-Week Low | $146.04 | $3.72 |
Enterprise Value | $59.91B | -$6.71M |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $235.3, down 0.79% on the day, but remains near its 52-week high. The stock exhibits a bullish technical signal with consistent earnings beats in recent quarters, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue for fiscal 2025 was $222.58 billion, with net income reaching $1.56 billion. Analyst consensus is strongly positive, with 18 buys and a $266.43 price target, reflecting confidence in the company's pharmaceutical and specialty business growth.
The outlook for CAH is favorable, driven by robust earnings performance and optimistic fiscal 2027 guidance. Key opportunities include sustained demand for specialty drugs and operational efficiency gains. Risks involve high debt levels, with a debt-to-asset ratio of 16.09 in 2025, and competitive pressures in the healthcare distribution sector. Investors should weigh strong analyst support against balance sheet leverage and market volatility.
22nd Century Group (XXII) trades at $4.31, down 0.92% on the day, with a neutral technical signal and bearish moving averages. The company shows deep unprofitability with a gross margin of -52.19% and net margin of -65.76%, though revenue was $7.05M in 2025. Recent corporate actions include a 20:1 reverse stock split in June 2026, and news highlights retail expansion for VLN reduced-nicotine cigarettes in California and New York.
The outlook remains speculative with high execution risk amid persistent losses, but analyst sentiment is bullish with 75% buy ratings. Key risks include negative cash flow from operations, regulatory hurdles for tobacco products, and the need for successful commercialization of VLN to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
